SCHEDULE 13G 0002052389 XXXXXXXX LIVE American Depositary Shares, each representing 200 Ordinary Shares 09/04/2025 0001614744 Purple Biotech Ltd. 74638P208 4 Oppenheimer Street, Science Park, Rehovot L3 7670104 Rule 13d-1(c) Orca Capital AG 2M 605000.00 0.00 605000.00 0.00 605000.00 N 9.9 CO All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 6,085,450 American Depositary Shares ("ADSs"), each representing 200 Ordinary Shares, outstanding immediately after giving effect to the completion of the Issuer's registered offering and excludes 2,000,000 ADSs issuable upon the exercise of Series B warrants and 395,000 ADSs issuable upon the exercise of pre-funded warrants held by the Reporting Person, subject to the 4.99% blocker (defined below). Pursuant to the terms of the pre-funded and Series B warrants, as described in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on September 5, 2025, the Reporting Person cannot exercise any of the pre-funded or Series B warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Ordinary Shares, including Ordinary Shares represented by ADSs (the "4.99% Blocker"). Purple Biotech Ltd. 4 Oppenheimer Street, Science Park,, Rehovot, ISRAEL, 7670104. Orca Capital AG Sperlring 2 85276 Hettenshausen Deutschland Germany Y 605,000 9.9% 605,000 0 605,000 0 Y N Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Orca Capital AG /s/ Thomas Konig 09/09/2025